Recombinant Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Recombinant Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Recombinant Vaccines Market

The recombinant vaccines market size was valued at USD 10.82 billion in 2019, and the market is now projected to grow to USD 25.32 billion by 2027, exhibiting a CAGR of 11.3% during the forecast period of 2019-2027.

Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the market switched to treating covid patients as priority over the other procedures which led the recombinant vaccines market growth. Additionally, manpower shortages affected manufacturing plants and slowed production due to movement restrictions and lockdowns in several regions. The pandemic has also had a negative impact on facial recognition door lock manufacturing and production facilities. The disruption in the supply chain and the decreased availability of labor, staff, and resources are the causes of this. The market is expected to grow slowly. However, subject to the treatment segment returning to its regular operations, the product demand will gradually revert to its historical estimations as lockdown requirements are gradually relaxed.

Benefits of recombinant properties to increase sales of genetically modified vaccines will boost recombinant vaccines market growth during forecast period. One of the most important and significant drivers of market growth is the full utilization of recombinant characteristics in providing efficacy and safety to patients receiving immunization. The vaccinations can be made quickly and in vast quantities, eliminating the possibility of vaccine shortages. These products are also free of infectious virus particles, lowering the risk of infection and making them safe to provide to immunocompromised patients. Because of the benefits of vaccines, producers are consciously focusing on producing novel medicines to combat viral infections using modern DNA technology, genomics, and other technological techniques.

Growing Vaccine Supply by UNICEF, WHO, and PAHO Due to Need for Rapid Immunization will boost recombinant vaccines market growth during forecast period. International organizations such as UNICEF and PAHO have lent a helping hand by distributing millions of vaccine doses to countries in need. As a result, 65% of the older population in the United States was vaccinated against influenza. Large amounts of vaccine dosage procurement by these organizations have resulted in a fall in the prevalence rate of several diseases as well as an increase in the population's immunity to those diseases.

Comprehensive Analysis of Recombinant Vaccines Market

The recombinant vaccines market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types, by Route of Administration, by Disease Indication and Distribution Channel. The Type segmentations include Subunit and Live Attenuated, By Route of Administration segmentations include Parenteral and Oral, By Disease Indication segmentations include Human Papillomavirus (HPV), Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others, By Distribution Channel segmentations include Hospital & Retail Pharmacies, Government Suppliers and Others.

The North America region lead the medical devices market by benefitting a market size of USD 4.97 billion in 2019 due to benefits of recombinant properties to increase sales of genetically modified vaccines and growing vaccine Supply by UNICEF, WHO, and PAHO Due to Need for Rapid Immunization.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These prominent key industry players include, GlaxoSmithKline plc. (U.K, Europe), Dynavax Technologies (California, U.S), Serum Institute of India Pvt. Ltd (India, Asia Pacific), Other Players these market players provide a level-playing competitive environment across the globe.

In December 2019, Merck achieved approval from the US Food and Drug Administration to unveil the Ebola vaccine, ERVEBO.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationBy Type

Subunit

Live Attenuated

By Route of Administration

Parenteral

Oral

By Disease Indication

Human Papillomavirus (HPV)

Hepatitis B

Rotavirus

Herpes Zoster

Meningococcal B

Others

By Distribution Channel

Hospital & Retail Pharmacies

Government Suppliers

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

The Middle East & Africa (South Africa, GCC and the Rest of the Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.